Cranoluten
Also known as: Brain bioregulator
Cranoluten (also called Brain bioregulator) is a khavinson bioregulator. Cranoluten is a peptide preparation extracted from brain tissue and marketed in the Khavinson tradition for central nervous system support.
For research use only.
Key Facts
- CAS
- 169772-06-9
- Molecular Weight (MW)
- 393.39 g/mol
- Half-life
- Not established
- FDA status
- Not Approved
- Administration Route
- —
- Frequency
- —
- Last updated
- Sep 26, 2026
- Reviewed
- Aug 30, 2026
- Targets
- CNS (proposed)
Research summary
Peptide preparation extracted from brain tissue and sold as a central nervous system bioregulator in the Khavinson tradition. It is a complex of low-molecular-weight peptides rather than a single defined molecule, so no specific sequence or mechanism can be assigned and batch composition is not standardised. No study of Cranoluten itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators. It is not FDA-approved.
Peptide Library's Cranoluten profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Not established for human use
- Frequency
- —
- Cycle
- —
- Administration Route
- —
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Cranoluten is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C15H27N3O8 |
|---|---|
| Molecular weight | 393.39 g/mol |
| CAS number | 169772-06-9 |
| Half-life | Not established |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Cranoluten is a peptide preparation extracted from brain tissue and marketed in the Khavinson tradition for central nervous system support. It is a complex of low-molecular-weight peptides rather than a single defined molecule, so no specific sequence, receptor or signalling pathway can be assigned to it, and batch composition is not standardised the way a single-entity drug would be. The proposed mechanism follows the series hypothesis that tissue-derived peptides act preferentially on the tissue they came from by influencing gene expression. No controlled human trials of this preparation have been published.
Origin
Synthetic short peptide bioregulator.
Targets
Studies
- Peptides and Ageing (class-level)
- Tissue-specific effects of peptides (class-level)
- Peptide bioregulation of aging: results and prospects (class-level evidence)
- Mechanisms underlying geroprotective effects of peptides (class-level evidence)
- Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b (class-level evidence)
Regulatory & research status
Cranoluten is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
Cranoluten side effects
Side Effects
- Not well characterized
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Cranoluten: frequently asked questions
What is Cranoluten?
Peptide preparation extracted from brain tissue and sold as a central nervous system bioregulator in the Khavinson tradition. It is a complex of low-molecular-weight peptides rather than a single defined molecule, so no specific sequence or mechanism can be assigned and batch composition is not standardised. No study of Cranoluten itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators. It is not FDA-approved.
How does Cranoluten work?
Cranoluten is a peptide preparation extracted from brain tissue and marketed in the Khavinson tradition for central nervous system support. It is a complex of low-molecular-weight peptides rather than a single defined molecule, so no specific sequence, receptor or signalling pathway can be assigned to it, and batch composition is not standardised the way a single-entity drug would be.
Is Cranoluten FDA approved?
No. Cranoluten is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Cranoluten?
Compounds most often compared with Cranoluten include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Class-level evidence — Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett, 2002External reference
- Class-level evidence — Tissue-specific effects of peptides. Bull Exp Biol Med, 2001External reference
- Class-level evidence — Peptide bioregulation of aging: results and prospects — Biogerontology, 2010External reference
- Class-level evidence — Mechanisms underlying geroprotective effects of peptides — Bull Exp Biol Med, 2002External reference
- Class-level evidence — Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b — Mol Biol (Mosk), 2019External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Sep 26, 2026 · Version 2
This Cranoluten profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Cranoluten research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →